Valion Bio, Inc. quarterly report, Q3 FY2022

Business context and reporting period

The supplied filing is Tivic Health Systems, Inc.’s (Nasdaq: TIVC) unaudited Form 10-Q for the quarter and nine months ended September 30, 2022. This differs from the request metadata, which names Valion Bio, Inc.; the summary below covers the issuer identified in the filing. Tivic develops drug-free bioelectronic treatments and sells its FDA-approved ClearUP sinus-treatment device through direct-to-consumer and retail channels.

Financial performance and position

Amounts below are in millions, except per-share data and percentages.

• Revenue increased 72% in Q3 and 65% for the nine-month period. Unit sales rose 37% in both comparisons; direct-to-consumer sales grew while retail unit sales declined following the discontinuation of less profitable reseller channels.
• For the nine months, operating cash use was $6.692 million, versus $2.852 million a year earlier. Investing cash use was $0.011 million; financing provided $0.056 million. Cash fell by $6.647 million, from $12.975 million to $6.328 million.
• At September 30, cash was $6.328 million, working capital was approximately $5.6 million, and accumulated deficit was $27.4 million. Total liabilities were $2.436 million, primarily accounts payable and operating lease liabilities; the filing reports no outstanding borrowings at quarter-end.
• Inventory increased to $0.761 million from $0.429 million, partly as a response to supply constraints. The company reported no off-balance-sheet arrangements.

Material changes, outlook, and risks

• Operating expenses rose substantially year over year. Nine-month increases included R&D of $0.730 million, sales and marketing of $1.196 million, and general and administrative expenses of $2.867 million. G&A included acquisition-related legal and consulting costs, higher staffing and D&O insurance, relocation costs, and public-company expenses.
• Management expects continued operating losses and says current cash and financial resources may be insufficient for the 12 months following issuance of the statements. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
• On October 7, 2022, the company agreed to acquire substantially all operating assets of Reliefband for $33.5 million, subject to adjustments and closing conditions; up to $1.5 million may, at the company’s election, be paid in restricted stock. Closing depends in part on financing. The October 26 Form S-1 for a proposed financing was not yet effective and required amendment before an offering could begin. The acquisition agreement could be terminated if closing had not occurred by February 6, 2023; specified termination circumstances include a $0.2 million breakup fee tied to failure to publicly file the financing registration statement.
• On October 21, the company entered a three-year, non-exclusive manufacturing agreement with Microart. Management expects it to reduce manufacturing costs, but the filing provides no quantified savings estimate.
• Management cites supply shortages, higher electronic-component costs, longer lead times, inflation, recession risk, COVID-19-related disruption, and geopolitical uncertainty as risks to production, margins, forecasting, and access to capital. A single California vendor handled all contract manufacturing in 2022.
• Management expects expenses to rise with product development and market expansion, but gives no numerical revenue, margin, or profitability guidance. Profitability timing is uncertain.
• Disclosure controls were assessed as effective. The company also disclosed a material weakness in internal control over financial reporting for 2020 and 2021, relating to staffing, segregation of duties, and inventory cost accounting; remediation efforts were underway.
• The company reported no material pending litigation or contingencies known to management. It had $6.0 million in money-market funds and reported cash deposits exceeding FDIC insurance limits by $5.8 million.

Important facts for investors to verify

1. Confirm the issuer identity: the supplied filing is for Tivic Health Systems, Inc. (TIVC), not Valion Bio, Inc.
2. Track the proposed financing’s effectiveness, amount and terms, and whether it provides sufficient capital for operations and the Reliefband purchase.
3. Verify whether the Reliefband acquisition closes, its final consideration and funding mix, and any integration or operating impacts.
4. Monitor cash burn, working capital, and the going-concern uncertainty, alongside progress toward reducing operating costs and improving gross margin.
5. Assess whether supply availability, component pricing, manufacturing diversification, and the Microart agreement materially affect costs and fulfillment.
6. Review subsequent disclosures on remediation of the material weakness and any further equity issuance or dilution.